F Bani-Sadr

Summary

Country: France

Publications

  1. doi request reprint Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response
    F Bani-Sadr
    Groupe Hospitalier Universitaire Est, INSERM U 707, Universite Pierre et Marie Curie, UMR S 707, UPMC Paris 6, Paris, France
    J Viral Hepat 19:431-5. 2012
  2. doi request reprint Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U707, France
    Clin Infect Dis 46:768-74. 2008
  3. doi request reprint Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors
    F Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U707, Paris, France
    J Viral Hepat 15:255-60. 2008
  4. ncbi request reprint Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin
    F Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris, INSERM U707, Paris, France
    J Viral Hepat 14:639-44. 2007
  5. ncbi request reprint Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM V707, Paris, France
    AIDS 20:525-31. 2006
  6. ncbi request reprint Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment
    Firouzé Bani-Sadr
    INSERM U707, Faculte de Medecine Hopital Saint Antoine, Paris, France
    Clin Infect Dis 41:1806-9. 2005
  7. ncbi request reprint Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U444, France
    J Acquir Immune Defic Syndr 40:47-52. 2005
  8. ncbi request reprint Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus
    F Bani-Sadr
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Paris, France
    Clin Infect Dis 39:1062-4. 2004
  9. doi request reprint [Treatment of chronic hepatitis C in HIV-infected patients]
    F Bani-Sadr
    Groupe Hospitalier Universitaire Est Hôpital Tenon INSERM U 707, Université Pierre et Marie Curie UPMC Paris 6, Paris France
    Gastroenterol Clin Biol 33:S97-S103. 2009
  10. doi request reprint Persistently normal alanine aminotransferase levels in HIV/HCV-coinfected patients: the role of steatosis
    F Bani-Sadr
    Groupe Hospitalier Universitaire Est, INSERM U 707, Universite Pierre et Marie Curie, Paris, France
    HIV Med 10:417-21. 2009

Collaborators

Detail Information

Publications14

  1. doi request reprint Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response
    F Bani-Sadr
    Groupe Hospitalier Universitaire Est, INSERM U 707, Universite Pierre et Marie Curie, UMR S 707, UPMC Paris 6, Paris, France
    J Viral Hepat 19:431-5. 2012
    ..Treatment of HCV infection should therefore be a priority in HIV-coinfected patients. Stavudine is associated with an increased risk of severe transaminitis...
  2. doi request reprint Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U707, France
    Clin Infect Dis 46:768-74. 2008
    ..We determined the prevalence and determinants of worsening fibrosis in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) who were receiving anti-HCV therapy...
  3. doi request reprint Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors
    F Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U707, Paris, France
    J Viral Hepat 15:255-60. 2008
    ..These findings show that severe weight loss is a frequent side effect of anti-HCV therapy in HIV / HCV-coinfected patients. The underlying mechanisms remain to be identified...
  4. ncbi request reprint Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin
    F Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris, INSERM U707, Paris, France
    J Viral Hepat 14:639-44. 2007
    ..26-0.49, P < 0.0001) and in patients receiving protease inhibitor-based antiretroviral therapy (OR, 0.51 95% CI, 0.30-0.86, P = 0.0114). Zidovudine discontinuation could help to avoid anaemia associated with anti-HCV therapy...
  5. ncbi request reprint Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM V707, Paris, France
    AIDS 20:525-31. 2006
    ..To evaluate the prevalence and severity of steatosis and possible interactions between steatosis, host factors, viral factors, and treatment for HIV infection in HIV-hepatitis C virus (HCV) coinfected patients...
  6. ncbi request reprint Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment
    Firouzé Bani-Sadr
    INSERM U707, Faculte de Medecine Hopital Saint Antoine, Paris, France
    Clin Infect Dis 41:1806-9. 2005
    ..02), and elevated total bilirubin level (OR, 7.9; 95% CI, 1.08-93.3; P<.03). Didanosine should thus not be given to patients with cirrhosis, particularly when treatments for HCV and HIV infections have to be administered concomitantly...
  7. ncbi request reprint Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U444, France
    J Acquir Immune Defic Syndr 40:47-52. 2005
    ..To evaluate the incidence, clinical features, and risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving anti-HCV therapy...
  8. ncbi request reprint Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus
    F Bani-Sadr
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Paris, France
    Clin Infect Dis 39:1062-4. 2004
    ..The use of combination therapy with lamivudine and tenofovir for the treatment of HBV infection is very promising in the treatment of HIV/HBV coinfection...
  9. doi request reprint [Treatment of chronic hepatitis C in HIV-infected patients]
    F Bani-Sadr
    Groupe Hospitalier Universitaire Est Hôpital Tenon INSERM U 707, Université Pierre et Marie Curie UPMC Paris 6, Paris France
    Gastroenterol Clin Biol 33:S97-S103. 2009
    ....
  10. doi request reprint Persistently normal alanine aminotransferase levels in HIV/HCV-coinfected patients: the role of steatosis
    F Bani-Sadr
    Groupe Hospitalier Universitaire Est, INSERM U 707, Universite Pierre et Marie Curie, Paris, France
    HIV Med 10:417-21. 2009
    ..We analysed factors associated with persistently normal ALT levels, defined as at least three consecutive normal ALT values over a 6-month period, in a group of 381 HIV/HCV-coinfected patients...
  11. ncbi request reprint [Metastatic cancer of the prostate in a 40-year-old HIV-infected male patient]
    A Furco
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Paris
    Presse Med 32:644-5. 2003
    ..Cancer of the prostate in HIV-infected patients has rarely been reported in the literature...
  12. doi request reprint Liver stiffness values in HIV-infected patients with isolated anti-hepatitis B core antibodies
    C Chakvetadze
    Service des Maladies Infectieuses et Tropicales, Hopital Tenon, 4, rue de la Chine, 75970 Paris Cedex 20, France
    Med Mal Infect 43:222-5. 2013
    ..Hepatitis B reactivation has been observed in HIV-infected patients with isolated anti-HBc. However, the impact of isolated anti-HBc on liver fibrosis is not known in this population...
  13. ncbi request reprint [Metastatic cancer of the prostate in a young 40 year-old HIV-infected male patient]
    A Furco
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Paris
    Presse Med 32:930-1. 2003
    ..Cancer of the prostate in HIV-infected patients has rarely been reported in the literature...
  14. doi request reprint Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008
    L Michel
    INSERM U669, Paris, France
    J Viral Hepat 17:650-60. 2010
    ....